Company Overview and News

 
TransCanada's (TRP) CEO Russ Girling on Q4 2017 Results - Earnings Call Transcript

2018-02-16 seekingalpha
Good day, ladies and gentlemen. Welcome to the TransCanada Corporation 2017 Fourth Quarter Results Conference Call. I would now like to turn the meeting over to Mr. David Moneta, Vice President, Investor Relations. Please go ahead, Mr. Moneta.

1
TransCanada's Sleepy Cash Flow Cow

2018-01-03 seekingalpha
Power plants and unregulated storage facilities may be a sleepy business, but they do generate a lot of cash flow.

 
TransCanada's History And Growth Support Continued Dividend Growth

2017-12-26 seekingalpha
TransCanada has recently completed a $13 billion acquisition of Columbia Pipeline Partners and accomplished $0.25 billion in synergies increasing its cash flow here.

 
TransCanada Reports Solid Third Quarter 2017 Financial Results; Diversified, Low-Risk Business Strategy Continues to Drive Performance

2017-11-09 marketwired
CALGARY, ALBERTA--(Marketwired - Nov. 9, 2017) - TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada or the Company) today announced net income attributable to common shares for third quarter 2017 of $612 million or $0.70 per share compared to a net loss of $135 million or $0.17 per share for the same period in 2016. Comparable earnings for third quarter 2017 were $614 million or $0.70 per share compared to $622 million or $0.

 
Columbia Pipeline Partners EX-24 DOCUMENT

2017-10-04 sec.gov
POWER OF ATTORNEY FOR EXECUTING FORM ID, FORMS 3, FORMS 4 AND FORMS 5, FORM 144 AND SCHEDULE 13D AND SCHEDULE 13G The undersigned hereby constitutes and appoints Robert E. Smith and Samuel K. Lee, with full power of substitution, as the undersigned's true and lawful attoney-in-fact to: (1) Execute for and on behalf of the undersigned a Form ID (including amendments thereto), or any other forms prescribed by the Securi

 
Columbia Pipeline Partners EX-24 DOCUMENT

2017-10-04 sec.gov
POWER OF ATTORNEY FOR EXECUTING FORM ID, FORMS 3, FORMS 4 AND FORMS 5, FORM 144 AND SCHEDULE 13D AND SCHEDULE 13G The undersigned hereby constitutes and appoints Robert E. Smith and Samuel K. Lee, with full power of substitution, as the undersigned's true and lawful attoney-in-fact to: (1) Execute for and on behalf of the undersigned a Form ID (including amendments thereto), or any other forms prescribed by the Securi

 
Columbia Pipeline Partners FORM 8-K (Current Report/Significant Event)

2017-10-04 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 18, 2015 (March 13, 2015)     Columbia Pipeline Partners LP (Exact name of registrant as specified in its charter)       Delaware   001-36835   51-0658510 (State or Other Jurisdiction of Incorporation or Organization)   (Commission File Number)   (IRS Empl

 
Columbia Pipeline Partners EX-99.1

2017-06-21 sec.gov
CPPL-EX99.1_2015.3.31 Exhibit 99.1       5151 San Felipe   Houston, Texas 77056   NYSE: CPPL NEWS RELEASE   April 30, 2015 FOR ADDITIONAL INFORMATION: Investors: Media: Bruce Connery James Yardley Vice President, Investor Relations Director, External Communications (713) 386-3603 (713) 386-3366 [email protected] [email protected] Columbia Pipeline Partners LP Reports Solid First Quarter Results • Completed initial public offering • Generated $18.

 
Columbia Pipeline Partners 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
8-K Header 1Q15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant To Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015   Columbia Pipeline Partners LP (Exact name of registrant as specified in its charter)             Delaware   001-36835   51-0658510 (State or other jurisdiction of incorporation or organization)   Commission file number   (I.

 
Columbia Pipeline Partners EX-99.1

2017-06-21 sec.gov
EX-99.1 Exhibit 99.1   Creating A Premier Pipeline, Midstream and Storage Company Bob Skaggs CEO Glen Kettering President Steve Smith CFO Pre-Separation Update May 14, 2015   Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are subject to various risks and uncertainties. Examples of forward-looking statements in this presentation include statements and expectations regarding future div

 
Columbia Pipeline Partners FORM 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant To Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015     Columbia Pipeline Partners LP (Exact Name of Registrant as Specified in Charter)       Delaware   001-36835   51-0658510 (State or other jurisdiction of incorporation)   (Commission file number)   (IRS Employer Identification No.

 
Columbia Pipeline Partners EX-99.1

2017-06-21 sec.gov
EX-99.1 Exhibit 99.1 Columbia Pipeline Group, Inc. Announces Launch of $2.75 Billion Private Placement of Senior Notes HOUSTON, Texas, May 19, 2015—Columbia Pipeline Group, Inc. (the “Company”), a wholly owned subsidiary of NiSource Inc. (“NiSource”) (NYSE: NI) announced today that, subject to market conditions, it intends to offer $2.75 billion in aggregate principal amount of its senior unsecured notes in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as am

 
Columbia Pipeline Partners FORM 8-K (Current Report/Significant Event)

2017-06-21 sec.gov
Form 8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2015     Columbia Pipeline Partners LP (Exact name of registrant as specified in its charter)       Delaware   001-36835   51-0658510 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification

 
Columbia Pipeline Partners EX-4.2

2017-06-21 sec.gov
EX-4.2 Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT by and among Columbia Pipeline Group, Inc., Subsidiary Guarantors, listed on the signature pages hereof, and J.P. Morgan Securities LLC Mitsubishi UFJ Securities (USA), Inc. Scotia Capital (USA) Inc. as representatives of the Initial Purchasers Dated as of May 22, 2015 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 22, 2015, by and among Columbia Pipeline Group, Inc.

 
Columbia Pipeline Partners EX-4.1

2017-06-21 sec.gov
EX-4.1 Exhibit 4.1       COLUMBIA PIPELINE GROUP, INC. as Issuer and CPG OPCO LP, COLUMBIA ENERGY GROUP, and CPG OPCO GP LLC as Guarantors and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 22, 2015     2.45% Senior Notes due 2018 3.30% Senior Notes due 2020 4.50% Senior Notes due 2025 and 5.80% Senior Notes due 2045       CROSS-REFERENCE TABLE*   TRUST INDENTURE ACT SECTION    INDENTURE SECTION 310(a)(1)    6.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 198281107